Zelira Therapeutics Limited (FRA:G1G)

Zelira Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	0	0.09	0.3	1.54	0.66
Revenue	0	0.09	0.3	1.54	0.66
Revenue Growth (YoY)	-99.31%	-68.47%	-80.45%	132.26%	-
Cost of Revenue	0.8	0.33	0.63	0.94	0.23
Gross Profit	-0.8	-0.23	-0.33	0.6	0.44
Selling, General & Admin	1.67	2.33	5.89	7.39	5.85
Research & Development	2.66	2.81	1.34	1.4	2.08
Other Operating Expenses	0.1	0.01	0.12	0.23	0.11
Operating Expenses	3.52	5.66	6.84	13.81	9.82
Operating Income	-4.32	-5.9	-7.16	-13.21	-9.38
Interest Expense	-0.41	-0.74	-0.08	-0.05	-0.04
Interest & Investment Income	-	0	0	0.01	0
Other Non Operating Income (Expenses)	0.88	0.64	1.03	0.9	1.05
EBT Excluding Unusual Items	-3.85	-5.99	-6.21	-12.35	-8.37
Impairment of Goodwill	-	-30.75	-	-	-
Gain (Loss) on Sale of Investments	-	-	-0.06	-0.07	-0.18
Pretax Income	-3.85	-36.74	-6.27	-12.41	-8.55
Earnings From Continuing Operations	-3.85	-36.74	-6.27	-12.41	-8.55
Minority Interest in Earnings	0.22	0.17	0.7	0.47	-
Net Income	-3.63	-36.57	-5.57	-11.95	-8.55
Net Income to Common	-3.63	-36.57	-5.57	-11.95	-8.55
Shares Outstanding (Basic)	11	11	10	8	7
Shares Outstanding (Diluted)	11	11	10	8	7
Shares Change (YoY)	1.20%	12.70%	25.19%	21.25%	36.81%
EPS (Basic)	-0.32	-3.22	-0.55	-1.49	-1.29
EPS (Diluted)	-0.32	-3.22	-0.55	-1.49	-1.29
Free Cash Flow	-4.91	-4.39	-7.25	-9.43	-8.62
Free Cash Flow Per Share	-0.43	-0.39	-0.72	-1.17	-1.30
Gross Margin	-	-246.37%	-108.91%	39.05%	65.59%
Operating Margin	-658713.11%	-6211.63%	-2379.17%	-857.21%	-1414.10%
Profit Margin	-553029.27%	-38513.04%	-1850.75%	-775.36%	-1288.84%
Free Cash Flow Margin	-747996.04%	-4621.90%	-2407.36%	-611.91%	-1299.02%
EBITDA	-4.17	-5.54	-6.74	-12.73	-9.02
D&A For EBITDA	0.15	0.35	0.42	0.47	0.36
EBIT	-4.32	-5.9	-7.16	-13.21	-9.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.